Novo Holdings, the controlling shareholder of Danish weight problems drugmaker Novo Nordisk, stated on Wednesday it plans to take a position round $200 million in quantum computing startups.
The corporate, the funding arm of the Novo Nordisk Basis, has 77% of voting shares in Novo Nordisk, which is understood for producing blockbuster weight problems drug Wegovy and diabetes therapy Ozempic.

Elevate Your Tech Prowess with Excessive-Worth Ability Programs

Providing FacultyCourseWeb site
Indian Faculty of EnterpriseISB Skilled Certificates in Product AdministrationGo to
Indian Faculty of EnterpriseISB Product AdministrationGo to
MITMIT Know-how Management and InnovationGo to

Consultants consider quantum computing could show to be among the many most transformational technological developments of the twenty first century.

Tech corporations and governments alike have been working to create machines that benefit from quantum mechanics, able to making scientific calculations that will in any other case take most computer systems thousands and thousands of years.

Asserting the information on Wednesday, Novo Holdings stated it needed to assist construct an ecosystem of quantum computing startups, with a selected deal with life sciences corporations based mostly in Nordic international locations.

By making use of the expertise to the event of prescription drugs and different life sciences, quantum computing corporations may considerably pace up the drug discovery course of.

Uncover the tales of your curiosity


Soren Moller, managing associate of seed investments at Novo Holdings, stated: “Quantum expertise is a disruptive and transformative subject that may revolutionise numerous sectors and tackle international challenges.” He added: “Our final purpose is to create, develop and develop robust quantum expertise corporations within the Nordics.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here